Fatty Acid Supplementation and Retinopathy of Prematurity: Secondary Analysis of a Randomized Clinical Trial

Abstract:

No abstract available

Summary

Retinopathy of prematurity (ROP) causes visual impairment in premature infants, even with timely treatment.

In the Mega Donna Mega (MDM) randomized clinical trial, enteral supplementation with arachidonic acid (AA) and docosahexaenoic acid (DHA) reduced the risk for severe ROP in extremely preterm infants by 50%.^1,2 We report which risk factors were influenced by AA and DHA and their interactions with severe ROP.


Plain language summary

This secondary analysis of a randomized clinical trial examines what risk factors for retinopathy of prematurity are influenced by supplementation with arachidonic acid and docosahexaenoic acid and their interactions with severe retinopathy of prematurity.